Condition: Head and Neck Squamous Cell Carcinoma · Brain Metastases · Sponsor: Vanderbilt-Ingram Cancer Center
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
This description comes directly from the study's public registry record.
Vanderbilt-Ingram Services for Timely Access · 800-811-8480 · cip@vumc.org
Always discuss trial participation with your own doctor first.
| Vanderbilt University/Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996432